Company / Shareholders' Equity
Krystal Biotech, Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.2B
FY2025
5-year range
$522.2M / $1.2B
FY2021-FY2025
Trend
+28.9%
vs FY2024
Sector context
#39 of 213
Health Care
What the data says
Krystal Biotech, Inc.'s shareholders' equity of $1.2B is higher than 82% of companies in the Health Care sector (FY2025). Shareholders' Equity has increased for 3 consecutive years, from $522M in FY2022 to $1.2B in FY2025.
Based on SEC 10-K filings.
$1.2B in FY2025 with a 5-year CAGR of +33.1%. Top quartile in the Health Care sector.
Improved from $779M to $1.2B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +32.7%
- 5-Year CAGR
- +33.1%
- 10-Year CAGR
- -
Sector benchmark
-52.2% below sector average
Key checks
Key Insights
- Krystal Biotech, Inc.'s shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +33.1%, indicating consistent growth.
- In FY2025, shareholders' equity increased 28.9% year-over-year.
- Ranks #39 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 5.66 (safe zone, above 2.9 threshold)
- Strong profit margin: 30.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2B | +28.9% |
| FY2024 | $946.4M | +21.5% |
| FY2023 | $778.6M | +49.1% |
| FY2022 | $522.2M | -12.0% |
| FY2021 | $593.6M | +103.2% |
| FY2020 | $292.1M | +43.9% |
| FY2019 | $202.9M | +79.2% |
| FY2018 | $113.2M | +128.9% |
| FY2017 | $49.5M | +17019.0% |
| FY2016 | $289.0K | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026